Pharming Group (NASDAQ:PHAR) Sees Large Volume Increase - Time to Buy?

Key Points

• Pharming Group experienced a significant increase in trading volume, with 8,380 shares traded, marking a 14% rise from the previous session.
• The company's stock price increased by 3.8%, closing at $14.10, up from the previous close of $13.79.
• In its latest quarterly earnings report, Pharming Group surpassed expectations with $0.06 earnings per share and revenue of $93.20 million, exceeding analyst forecasts.

Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR - Get Free Report) saw an uptick in trading volume on Monday . 8,380 shares traded hands during trading, an increase of 14% from the previous session's volume of 7,321 shares.The stock last traded at $14.10 and had previously closed at $13.79.

Pharming Group Stock Up 3.8%

The firm has a market cap of $980.38 million, a PE ratio of -110.08 and a beta of 0.05. The company has a debt-to-equity ratio of 0.38, a quick ratio of 2.07 and a current ratio of 2.79. The company's 50-day simple moving average is $12.94 and its two-hundred day simple moving average is $10.80.

Pharming Group (NASDAQ:PHAR - Get Free Report) last announced its quarterly earnings results on Thursday, July 31st. The company reported $0.06 earnings per share for the quarter, beating the consensus estimate of ($0.10) by $0.16. The business had revenue of $93.20 million during the quarter, compared to analysts' expectations of $70.36 million. Pharming Group had a negative net margin of 2.19% and a negative return on equity of 3.31%. Pharming Group has set its FY 2025 guidance at EPS. On average, analysts predict that Pharming Group N.V. Sponsored ADR will post -0.2 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Pharming Group

An institutional investor recently raised its position in Pharming Group stock. Silverberg Bernstein Capital Management LLC lifted its stake in Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR - Free Report) by 8.6% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 52,147 shares of the company's stock after purchasing an additional 4,150 shares during the period. Silverberg Bernstein Capital Management LLC owned 0.08% of Pharming Group worth $557,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 0.03% of the company's stock.

Pharming Group Company Profile

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.